   Allergy Therapeutics plc Annual Report & Accounts 2012 www.allergytherapeutics.com www.pollinex.com Directors' remuneration report
Directors' remuneration report 
The Remuneration Committee
The Remuneration Committee comprised Stephen Smith 
 financial year. The Committee held four meetings during the 
past financial year. The principal purpose of the Committee is 
to determine and agree the directors' salary increases, annual 
bonuses, scope of pension arrangements and any changes in 
benefits. In addition, the Committee also agrees the share-
 Members Member since Attendance at   
   meetings  
   2011-12
   
 
 

Remuneration policy
The Committee's policy is to set remuneration packages for 
 of the highest calibre. Remuneration packages are designed 
 payments and awards of share-related compensation, which 
together constitute a potentially significant proportion of the 
total remuneration opportunity.
 following elements:
(i) Basic salary
 account personal performance, and benchmarked against the 
Comparator Group.
(ii) Taxable benefits
 and private medical insurance.
(iii) Share options
 later in this report and comprise grants made in prior years 
under previous approved and unapproved option schemes. 
Share options previously granted by Allergy Therapeutics 
 share options in Allergy Therapeutics plc, on substantially the 
same terms.
(iv) Long Term Incentive Plan
During the year ended 30 June 2012 provisional shares 
were awarded to directors and senior management under 
 (v) SAYE Plan
During the year ended 30 June 2012 no offer was made to 
 (vi) Bonus
 
a performance-related cash bonus based upon individual 
performance and achievement of personal and corporate 
objectives. Annual bonus payments are capped under service 
 the Remuneration Committee in September each year for the 
preceding financial year. 
 
(vii) Pension arrangements
 Service contracts

   
 Manuel Llobet 21 June 2012  12 months 

 
 
 
amended on 21 June 2012 to reflect the changes in his  
notice period to twelve months from the Company.  
 

   
 
 
 Stephen Smith 1 April 2012 3 months 
 Thomas Lander  2 May 2012 3 months 
 

  
 
 June 2012 to reflect a change in his notice period from 3 to 
 for work beyond his contractual four days per month when 
   Allergy Therapeutics plc Annual Report & Accounts 2012  www.allergytherapeutics.com www.pollinex.com 50 Directors' remuneration report
Directors' remuneration (audited information)
Details of remuneration of those who served as directors during the year are set out below.
          
        Year ended 30 June 2011
 
  Basic Bonus Taxable Fees Total Pension 
  salary for the year benefits 
             
 
 Manuel Llobet 195,188 47,188 11,170 - 253,546 27,690 
 
 Ian Postlethwaite 152,542 39,160 10,782 - 202,484 15,254 
 
 Peter Jensen 65,000 - - - 65,000 - 41,500 - 
 
 Stephen Smith
1
 - - - 36,000 36,000 - 
 
 Alejandro Weinstein 36,000 - - - 36,000 - 
 
 Ignace Goethals 36,000 - - - 36,000 - 
 
 Virinder Nohria 36,000 - - - 36,000 - 
 
 Thomas Lander  6,000 - - - 6,000 - - -
 
 Totals 526,730 86,348 21,952 36,000 671,030 42,944
 
1 
Mr Smith's fees are paid to SRS Business Enterprises Limited. 
   Allergy Therapeutics plc Annual Report & Accounts 2012 www.allergytherapeutics.com www.pollinex.com 51 Directors' remuneration report
Directors' share options and LTIPs
           
 
 

 
 Executive Directors         
 
 Manuel Llobet
1

1
 
 
 Ian Postlethwaite 
 
 

1

1
 - -  1,320,000 - - -
 
 Non-Executive Directors        
 
 Stephen Smith 
 
 Ignace Goethals 
 
 Virinder Nohria 100,000 - - - 100,000 - 45.0 15/12/2003 15/12/2013 
      
 
 Totals 4,893,500 1,080,000 - 400,000 250,000 5,323,500   
 
1   

 
 
 Stephen Smith
Chairman, Remuneration Committee
14 September 2012